Montag & Associates’s Blueprint Medicines BPMC Stock Holding History

Montag & Associates’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9	Closed	-$763	–	955
2025 Q1	$763	Buy	+9	New	+$878	﹤0.01%	970

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Montag & Associates's BPMC Position: Q2 2025 in Review

Montag & Associates sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 9 shares — an estimated $763 sold.

Montag & Associates first reported a position in BPMC in Q1 2025 and held it in 1 quarter. The position peaked at $763 in Q1 2025. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

Montag & Associates reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
Montag & Associates sold 9 Blueprint Medicines shares in Q2 2025, an estimated $763.
Montag & Associates first reported a position in Blueprint Medicines in Q1 2025 and held it in 1 quarter.
Montag & Associates's Blueprint Medicines position peaked at $763 in Q1 2025.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Montag & Associates's 13F filing for Q2 2025, filed 7 Aug 2025.